REGN Grants CEO Schleifer, CSO Yancopoulos 10-Year PSUs Capped at 2.7M, 2.9M Shares Each
· The NYC Memo
Regeneron Pharmaceuticals, Inc. granted one-time performance share units (PSUs) to CEO Leonard S. Schleifer and CSO George D. Yancopoulos, effective September 24, 2026. These PSUs, with a 10-year performance period ending December 31, 2035, replace annual equity awards until 2036 and require nearly $30 billion in new product annual revenues for maximum earnout.
The awards are capped at 2,700,000 PSUs for the CEO and 2,900,000 PSUs for the CSO, with earned shares subject to a mandatory holding period until February 2036.